Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 10/20 | 0.53 |
| ▸ | GRM5 | P41594 | 10/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31346243 | 0.89 | GRM1 (0.49) | GRM1GRM5CYP11B2NAMPTWNT3A | |
| SCHEMBL31227073 | 0.84 | WNT3A (0.61) | GRM1GRM5CYP11B2NAMPTWNT3A | |
| SCHEMBL171730 | 0.84 | WNT3A (0.61) | GRM1GRM5CYP11B2NAMPTWNT3A | |
| SCHEMBL25318823 | 0.84 | NAMPT (0.52) | GRM1GRM5CYP11B2NAMPTPDK4 | |
| SCHEMBL17478211 | 0.84 | GRM1 (0.52) | GRM1GRM5CYP11B2NAMPTWNT3A | |
| SCHEMBL29580742 | 0.84 | GRM1 (0.52) | GRM1GRM5CYP11B2NAMPTWNT3A | |
| SCHEMBL27461432 | 0.84 | GRM1 (0.51) | GRM1GRM5CYP11B2NAMPTWNT3A | |
| SCHEMBL31336142 | 0.84 | GRM5 (0.51) | GRM1GRM5CYP11B2NAMPTWNT3A | |
| SCHEMBL22324775 | 0.84 | GRM1 (0.52) | GRM1GRM5CYP11B2NAMPTWNT3A | |
| SCHEMBL30796705 | 0.84 | GRM1 (0.51) | GRM1GRM5CYP11B2NAMPTWNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4217342-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | Neuropore Therapies, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507607-A | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022067114-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | GRM1 110/4885GRM5 89/4885CYP11B2 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.